Please Wait.....
Report
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Industry Report I 2022-04-29 I 96 Pages I Global Markets Direct
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration - Drugs In Development, 2022, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.
Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Juvenile Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 1, 14 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Juvenile Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Juvenile Macular Degeneration (Stargardt Disease) - Overview
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
4P-Pharma SAS
Alkeus Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Belite Bio Inc
Biophytis SA
Brooklyn ImmunoTherapeutics Inc
Cardax Inc
Coave Therapeutics
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Fera Pharmaceuticals LLC
Generation Bio Co
Grupo Ferrer Internacional SA
IVERIC bio Inc
jCyte Inc
Katairo GmbH
Kubota Vision Inc
Lysoclear Inc
Mediphage Bioceuticals Inc
Nanoscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc
Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
4P-020 - Drug Profile
Product Description
Mechanism Of Action
ALK-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Aptamer to Inhibit CFD for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Product Description
Mechanism Of Action
ASP-7317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDX-301 - Drug Profile
Product Description
Mechanism Of Action
CTxABCA-4 - Drug Profile
Product Description
Mechanism Of Action
ecothiopate iodide - Drug Profile
Product Description
Mechanism Of Action
History of Events
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
FAB-111 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy To Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
GTSG - Drug Profile
Product Description
Mechanism Of Action
Jcell - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lead program in Stargardt disease - Drug Profile
Product Description
Mechanism Of Action
metformin - Drug Profile
Product Description
Mechanism Of Action
History of Events
miniABCA4: STGD1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QR-1011 - Drug Profile
Product Description
Mechanism Of Action
RAY-001 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
REV-0100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHP-261 - Drug Profile
Product Description
Mechanism Of Action
soraprazan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stargardt - Drug Profile
Product Description
Mechanism Of Action
Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
History of Events
STG-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
tinlarebant - Drug Profile
Product Description
Mechanism Of Action
History of Events
VMCO-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vutrisiran - Drug Profile
Product Description
Mechanism Of Action
History of Events
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Fera Pharmaceuticals announces FDA Orphan Designation of Phospholine Iodide for the treatment of Stargardt disease
Jan 25, 2022: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt macular degeneration patients
Jan 10, 2022: Nanoscope awarded key U.S. patent protecting its multi-characteristic Opsin Gene Therapy platform for reversing blindness
Aug 25, 2021: Aequus strengthens clinical experience in Stargardt disease with pediatric ophthalmology expertise
Jul 14, 2021: FDA grants Alkeus Pharmaceuticals Breakthrough Therapy designation for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt Disease
Jun 30, 2021: Belite Bio announces start of LBS-008 phase 3 Stargardt Disease trial
Mar 03, 2021: Nanoscope president to deliver talk on gene therapy for retinal diseases at Association for Ocular Pharmacology and Therapeutics conference
Jan 25, 2021: Nanoscope Therapeutics receives Orphan Drug Designation for gene therapy of blindness
Nov 24, 2020: Kubota Vision announces publication of Emixustats pharmacodynamic effects in patients with stargardt disease
Oct 28, 2020: reVision Therapeutics announces US FDA Grant of rare pediatric disease and orphan-drug designation for REV-0100 for the treatment of Stargardt disease
Aug 20, 2020: Kubota Vision receives orphan products clinical trials grants to Emixustat for stargardt disease
Jul 20, 2020: Belite Bio announces positive results from phase 1 clinical trials of LBS-008
May 01, 2020: Kubota Vision completes enrollment in the Emixustat phase 3 clinical trial in patients with Stargardt disease
Feb 13, 2020: Acucela provides update on Emixustat phase 3 clinical trial in patients with Stargardt disease
Jan 06, 2020: Acucela announces publication assessing the role of Emixustat Hydrochloride in retinal degeneration treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by 4P-Pharma SAS, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alnylam Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alpine Biotherapeutics Corp, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Applied Genetic Technologies Corp, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Beam Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Belite Bio Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Biophytis SA, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Cardax Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Coave Therapeutics, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Curative Biotechnology Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Fera Pharmaceuticals LLC, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Generation Bio Co, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by IVERIC bio Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by jCyte Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Katairo GmbH, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Kubota Vision Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Lysoclear Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Mediphage Bioceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Nanoscope Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Oak bay Biosciences Ltd, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ProQR Therapeutics NV, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ray Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ReVision Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Saliogen Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Shape Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Spark Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Splice Bio SL, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Stargazer Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, 2022
List of Figures
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security